T. Rowe Price Investment Management, Inc. Verve Therapeutics, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 2,352,599 shares of VERV stock, worth $18.4 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,352,599
Previous 2,425,073
2.99%
Holding current value
$18.4 Million
Previous $11.7 Million
13.04%
% of portfolio
0.01%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding VERV
# of Institutions
180Shares Held
76.4MCall Options Held
70.3KPut Options Held
194K-
Alphabet Inc. Mountain View, CA12.3MShares$96.7 Million4.92% of portfolio
-
Bvf Inc San Francisco, CA6.9MShares$54.1 Million1.46% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$51.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$31.4 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY4MShares$31.3 Million1.94% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $469M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...